# 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial

> **NCT07677566** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 20 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Patients

## Interventions

- **DRUG:** Darolutamide combined with 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT07677566
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677566, "177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*